Edmund Forey

Managing associate

Edmund is a managing associate in the commercial, IP and IT team, specialising in competition law. His practice includes advising on competition clearances for mergers and acquisitions, as well as on competition issues in commercial contexts such as distribution arrangements (including exclusive or selective distribution systems), internet sales and pricing strategies.

He also advises on matters affecting dominant companies, including pricing and refusal to supply, and regularly provides guidance on related areas including state aid, subsidy control and public procurement law.

I particularly enjoy working on complex matters with our clients but always strive to understand the commercial and economic drivers that matter to them because the legal considerations are always part of a bigger picture.

Edmund Forey, Managing associate

In addition, Edmund regularly assists acquirers and investors in securing regulatory clearances under the UK’s National Security and Investment Act (NSIA). Alongside his broad understanding of commercial law and contract drafting, Edmund has particular experience in the health sector. He has advised major government bodies on large-scale contracts, as well as on healthcare mergers and joint ventures, and on the Competition and Markets Authority’s private healthcare regime.

Edmund joined Penningtons Manches Cooper in 2017 from a national law firm. Before qualifying as a solicitor in 2009, he worked in the publishing and music industries. He holds a postgraduate diploma in EU competition law from King’s College London and regularly teaches on competition law and patent licensing as part of the IP Transactions Law and Practice course run by the UCL Institute of Brand & Innovation Law.

Recent work highlights

NHS service provider acquisition

Advising the acquirer of a private provider of services to the NHS on the operation of the NHS Standard Contract and on NHS commissioning and procurement structures.

UK R&D subsidy advice

Advising a government funding agency on the newly implemented UK subsidy regime and its implications for the award of grant funding for research and development and the commissioning of contract research.

National Security Clearances

Advising Oxford Science Enterprises, whose portfolio covers life sciences, health tech and deep tech, on the UK’s national security regime and managing clearances under that regime for its investments.

Phase II Merger

Advising Seedrs Limited through the phase 1 and phase 2 merger control processes with the Competition and Markets Authority.

AI health tech consortium

Advising a leading university on the establishment and operation of a centre for AI and medical imaging, including drafting joint venture agreements to bring together a consortium of universities and NHS trusts.